These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 33744052)

  • 21. Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysis.
    Gasparini R; Landa P; Amicizia D; Icardi G; Ricciardi W; de Waure C; Tanfani E; Bonanni P; Lucioni C; Testi A; Panatto D
    Hum Vaccin Immunother; 2016 Aug; 12(8):2148-2161. PubMed ID: 27163398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methods to evaluate serogroup B meningococcal vaccines: From predictions to real-world evidence.
    Borrow R; Taha MK; Giuliani MM; Pizza M; Banzhoff A; Bekkat-Berkani R
    J Infect; 2020 Dec; 81(6):862-872. PubMed ID: 32745637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parental awareness and utilization of meningococcal serogroup B vaccines in the United States.
    Srivastava A; Dempsey A; Galitsky A; Fahimi M; Huang L
    BMC Public Health; 2020 Jul; 20(1):1109. PubMed ID: 32664872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Review of the Epidemiology of Invasive Meningococcal Disease and Vaccination Strategies in North Africa.
    Taha MK; Presa J; Serra L
    Int J Infect Dis; 2021 Mar; 104():189-197. PubMed ID: 33227521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of Meningococcal Vaccines at Reducing Invasive Meningococcal Disease and Pharyngeal Neisseria meningitidis Carriage: A Systematic Review and Meta-analysis.
    McMillan M; Chandrakumar A; Wang HLR; Clarke M; Sullivan TR; Andrews RM; Ramsay M; Marshall HS
    Clin Infect Dis; 2021 Aug; 73(3):e609-e619. PubMed ID: 33212510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease.
    Scholz S; Schwarz M; Beck E; Meszaros K; Schneider M; Ultsch B; Greiner W
    Infect Dis Ther; 2022 Feb; 11(1):367-387. PubMed ID: 34877641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Economic evaluation of the introduction of 4CMenB (Bexsero®) in the national vaccine schedule in Spain].
    Ruiz-Montero R; Epstein D; Guzmán Herrador B; Espín Balbino J
    Gac Sanit; 2020; 34(4):318-325. PubMed ID: 31776044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study.
    Abara WE; Bernstein KT; Lewis FMT; Schillinger JA; Feemster K; Pathela P; Hariri S; Islam A; Eberhart M; Cheng I; Ternier A; Slutsker JS; Mbaeyi S; Madera R; Kirkcaldy RD
    Lancet Infect Dis; 2022 Jul; 22(7):1021-1029. PubMed ID: 35427490
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Timing of meningococcal vaccination with 4CMenB (Bexsero®) in children with invasive meningococcal group B (MenB) disease in England.
    Ladhani SN; Campbell H; Amin-Chowdhury Z; Lucidarme J; Borrow R; Ramsay ME
    Vaccine; 2022 Mar; 40(10):1493-1498. PubMed ID: 35148913
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The introduction of the meningococcal B (MenB) vaccine (Bexsero®) into the national infant immunisation programme--New challenges for public health.
    Ladhani SN; Campbell H; Parikh SR; Saliba V; Borrow R; Ramsay M
    J Infect; 2015 Dec; 71(6):611-4. PubMed ID: 26433141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protecting UK adolescents and adults against meningococcal serogroup B disease.
    Vyse A; Ellsbury G; Madhava H
    Expert Rev Vaccines; 2018 Mar; 17(3):229-237. PubMed ID: 29374982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Health and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programme.
    Tirani M; Meregaglia M; Melegaro A
    PLoS One; 2015; 10(4):e0123383. PubMed ID: 25874805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost calculator for mass vaccination response to a US college campus outbreak of serogroup B meningococcal disease.
    La EM; Talbird SE; Kanadanian KV; Huang L; Fain J; Srivastava A
    Hum Vaccin Immunother; 2019; 15(4):978-986. PubMed ID: 30526279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of invasive Neisseria meningitidis isolates recovered from children in Turkey during a period of increased serogroup B disease, 2013-2017.
    Ceyhan M; Ozsurekci Y; Lucidarme J; Borrow R;
    Vaccine; 2020 Apr; 38(19):3545-3552. PubMed ID: 32199701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Public Health Impact and Cost-Effectiveness Analysis of 4-Component Meningococcal Serotype B Vaccination for Infants in France.
    de Pouvourville G; Breau-Brunel M; Loncle-Provot V; Beck E; Gaugain L; Nachbaur G; Pribil C
    Pharmacoecon Open; 2024 Jul; 8(4):539-557. PubMed ID: 38780884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meningococcal serogroup B vaccination series initiation in the United States: A real-world claims data analysis.
    Packnett ER; Zimmerman NM; Novy P; Morgan LC; Chime N; Ghaswalla P
    Hum Vaccin Immunother; 2023 Dec; 19(1):2165382. PubMed ID: 36715008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Background Paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease.
    Hellenbrand W; Koch J; Harder T; Bogdan C; Heininger U; Tenenbaum T; Terhardt M; Vogel U; Wichmann O; von Kries R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1314-43. PubMed ID: 26487381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meningococcal Carriage Evaluation in Response to a Serogroup B Meningococcal Disease Outbreak and Mass Vaccination Campaign at a College-Rhode Island, 2015-2016.
    Soeters HM; Whaley M; Alexander-Scott N; Kanadanian KV; MacNeil JR; Martin SW; McNamara LA; Sicard K; Vanner C; Vuong J; Wang X; Bandy U; Patel M;
    Clin Infect Dis; 2017 Apr; 64(8):1115-1122. PubMed ID: 28158417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical data supporting a 2-dose schedule of MenB-FHbp, a bivalent meningococcal serogroup B vaccine, in adolescents and young adults.
    Beeslaar J; Absalon J; Balmer P; Srivastava A; Maansson R; York LJ; Perez JL
    Vaccine; 2018 Jun; 36(28):4004-4013. PubMed ID: 29861182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of national vaccination policies to prevent serogroup B meningococcal disease.
    Sulis G; Horn M; Borrow R; Basta NE
    Vaccine; 2022 Jun; 40(26):3647-3654. PubMed ID: 35581099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.